The Rapid Diagnosis of MCI and Depression in Patients Ages 60 and Over

Launched by MIRO HEALTH · Aug 23, 2023

Keywords

ClinConnect Summary

This clinical trial is studying ways to better diagnose Mild Cognitive Impairment (MCI) and late-life depression (LLD) in people aged 60 and older. MCI can lead to Alzheimer's disease, and LLD often occurs alongside it. By improving a special technology called artificial intelligence (AI), the researchers hope to accurately identify these conditions. This is important because early detection can help improve the quality of life for patients and support future treatments.

To participate in the trial, you need to be at least 60 years old. You might be eligible if you have been diagnosed with LLD or have symptoms of it, or if you have been diagnosed with MCI or notice a gradual decline in your memory or thinking skills. Participants will undergo assessments using the AI technology to help with diagnosis. It’s also important to note that people with certain medical histories or those taking specific medications may not be eligible. If you meet the criteria, joining this trial could contribute to important advancements in understanding and treating these conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • LLD: Age 60 or over; diagnosis of LLD or symptoms consonant with LLD; PHQ-9 score from 15 to 27
• • MCI: Age 60 or over; diagnosis of MCI or self-reported insidious onset and continued worsening of cognitive decline; intact activities of daily living
• • HC: Age 60 or over
• Exclusion Criteria:
• • Age 59 or younger; history of unresolved neurological or psychiatric conditions; current medications known to affect cognition; history of substance abuse; unable to perform activities of daily living; change in employment status due to condition